Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)
Sponsor: Merck Sharp & Dohme LLC
Summary
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. Researchers are doing this trial to learn if a trial medicine called MK-8690 can treat symptoms of active RA in people who are taking MTX. The goal of this study is to learn if MK-8690 works better than placebo to improve RA symptoms.
Official title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Participants With Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-11-23
Completion Date
2028-11-28
Last Updated
2026-10-26
Healthy Volunteers
No
Conditions
Interventions
MK-8690
Solution for SC injection
Placebo
Solution for SC injection
Methotrexate (MTX)
Background therapy - variable dose strength with route of administration per approved product label